2021 Fiscal Year Final Research Report
Development of Biodegradable Drug Eluting Beads (DEB) for the novel treatment of Chronic Pulmonary Aspergillosis
| Project/Area Number |
19K17179
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 52040:Radiological sciences-related
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 呼吸器感染症 / 慢性肺アスペルギルス症 / 喀血 / ドラッグリバリーシステム / 生分解性ポリマー |
|---|
| Outline of Final Research Achievements |
Pulmonary aspergillosis is a chronic infection of the lungs. The pulmonary aspergillosis causes massive hemoptysis, and the fatality rate is reported to be 11-50%. Bronchial artery embolization, in which gelatin sponge strips or embolic beads are injected to achieve hemostasis, has been proven effective in the short term, but more than half of the patients have recurrent hemoptysis after one year. Because current embolization materials do not provide long-term hemostatic and antifungal effects, we developed a new embolization material with new functions. In this study, we generated novel drug-eluting beads (DEBs) using antifungal drugs, oil-based contrast media, and biodegradable polymers, and confirmed their engineering properties and antifungal effects.
|
| Free Research Field |
生体医工学
|
| Academic Significance and Societal Importance of the Research Achievements |
喀血に対する単純な血管塞栓術と経静脈的抗真菌薬の併用は標準的だが難治性である．トリアゾール系抗真菌薬のボリコナゾールは高い血中濃度では肝不全や完全失明に至る例があり，定期的な血中濃度測定が推奨されている．本研究成果によるビーズを用いることで，血管塞栓効果とともに感染局所のみに高い薬物濃度を維持することが出来，有効性と安全性を両立できる可能性がある．肺アスペルギルス症の治療において血管内からのアプローチはかつて存在せず，同分野の治療方針を変革し得る研究である．
|
